| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00 |
| filingDate |
2001-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d0a271ce6443e5cfde4cd3bad8e4db3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0be8bc5c5bb8e8c17d90752300d8fa99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d744d22ab5a0c832f9e21e569947ffc |
| publicationDate |
2003-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2003220313-A1 |
| titleOfInvention |
Selective nuclear receptor-targeted systems for delivery of cytotoxins to cancer cells for targeted photodynamic therapy |
| abstract |
An estrogen/antiestrogen-porphyrin conjugate, their composition and methods for their use are claimed. The active compounds of the invention are conjugates consisting of an estrogen or anti estrogen portion, tether or linker portion and a porphyrin portion. The method of invention exploits an active process that involves strong and specific interactions between nuclear receptor and its cognate ligand. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2867189-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018318388-A1 |
| priorityDate |
2000-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |